Abstract : <p>Totally implantable access ports (TIAPs) are generally used in oncology patients. A total of 89 consecutive oncology patients, between 2016 to 2019 were enrolled to receive TIAP inserts via an internal jugular vein (IJV) or subclavian vein (SV). Data of early/late complications were prospectively collected. The exclusion criteria were having an active infection and coagulopathy (platelets count &lt; 50 000/&micro;l, INR &gt; 2 or prothrombin time &gt; 18s) at the time of CVAP insertion. For all the patients 8 French ports were used as CVAP and patients were randomly divided into 2 groups of CVAP venous puncture site: Subclavian or Internal jugular vein. Thirty-two patients (36%) were male and 57 (64%) were female. The median age of participants was 55. Chemotherapy ports were implanted through Subclavian and jugular vein in 47(52.8%) and 42 (47.2%) patients respectively. No differences were found in early and late complication rates. In conclusion, we observed that both implantation approaches were feasible and safe. If the circumstances do not permit a puncture of the jugular vein, or if the jugular vein should be preserved for central venous lines, a fluoroscopy-guided or also sonographically guided puncture of the subclavian vein can be a safe alternative.</p>